[go: up one dir, main page]

WO2017177024A8 - Méthodes de traitement de troubles oculaires - Google Patents

Méthodes de traitement de troubles oculaires Download PDF

Info

Publication number
WO2017177024A8
WO2017177024A8 PCT/US2017/026385 US2017026385W WO2017177024A8 WO 2017177024 A8 WO2017177024 A8 WO 2017177024A8 US 2017026385 W US2017026385 W US 2017026385W WO 2017177024 A8 WO2017177024 A8 WO 2017177024A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
ocular disorders
treating ocular
treating
disorders
Prior art date
Application number
PCT/US2017/026385
Other languages
English (en)
Other versions
WO2017177024A1 (fr
Inventor
Douglas Michael Ackermann
James Loudin
Kenneth J. Mandell
Original Assignee
Oyster Point Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112018070497-0A priority Critical patent/BR112018070497B1/pt
Priority to US16/091,830 priority patent/US10709707B2/en
Priority to KR1020187032218A priority patent/KR102485299B1/ko
Priority to CA3020170A priority patent/CA3020170A1/fr
Priority to CN202210040168.XA priority patent/CN114432313A/zh
Priority to JP2018553080A priority patent/JP7090551B2/ja
Priority to IL299204A priority patent/IL299204A/en
Priority to MX2018012230A priority patent/MX385698B/es
Priority to CN201780034734.3A priority patent/CN109310692B/zh
Priority to DK17718304.3T priority patent/DK3439661T3/da
Priority to AU2017248276A priority patent/AU2017248276B2/en
Priority to MYPI2018001700A priority patent/MY199237A/en
Priority to NZ746468A priority patent/NZ746468A/en
Priority to EP21189296.3A priority patent/EP3970724A1/fr
Priority to ES17718304T priority patent/ES2893126T3/es
Application filed by Oyster Point Pharma, Inc. filed Critical Oyster Point Pharma, Inc.
Priority to KR1020237000103A priority patent/KR102512777B1/ko
Priority to CN202210034408.5A priority patent/CN114533737B/zh
Priority to EA201892265A priority patent/EA201892265A1/ru
Priority to SG11201808650QA priority patent/SG11201808650QA/en
Priority to EP17718304.3A priority patent/EP3439661B1/fr
Publication of WO2017177024A1 publication Critical patent/WO2017177024A1/fr
Priority to IL262102A priority patent/IL262102B/en
Priority to PH12018502154A priority patent/PH12018502154A1/en
Priority to ZA2018/07438A priority patent/ZA201807438B/en
Publication of WO2017177024A8 publication Critical patent/WO2017177024A8/fr
Priority to US16/852,225 priority patent/US20200345734A1/en
Priority to IL290069A priority patent/IL290069B2/en
Priority to JP2022095460A priority patent/JP2022120125A/ja
Priority to JP2024086805A priority patent/JP2024103594A/ja
Priority to US18/825,758 priority patent/US20250000861A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes et des formulations pharmaceutiques pour traiter des troubles oculaires.
PCT/US2017/026385 2016-04-07 2017-04-06 Méthodes de traitement de troubles oculaires WO2017177024A1 (fr)

Priority Applications (28)

Application Number Priority Date Filing Date Title
ES17718304T ES2893126T3 (es) 2016-04-07 2017-04-06 Métodos de tratamiento de afecciones oculares
KR1020187032218A KR102485299B1 (ko) 2016-04-07 2017-04-06 안구 장애의 치료 방법
CA3020170A CA3020170A1 (fr) 2016-04-07 2017-04-06 Methodes de traitement de troubles oculaires
CN202210040168.XA CN114432313A (zh) 2016-04-07 2017-04-06 治疗眼部病状的方法
JP2018553080A JP7090551B2 (ja) 2016-04-07 2017-04-06 眼状態の治療方法
IL299204A IL299204A (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions
MX2018012230A MX385698B (es) 2016-04-07 2017-04-06 Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
CN201780034734.3A CN109310692B (zh) 2016-04-07 2017-04-06 治疗眼部病状的方法
DK17718304.3T DK3439661T3 (da) 2016-04-07 2017-04-06 Fremgangsmåder til behandling af øjenlidelser
AU2017248276A AU2017248276B2 (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions
MYPI2018001700A MY199237A (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions
NZ746468A NZ746468A (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions
EP21189296.3A EP3970724A1 (fr) 2016-04-07 2017-04-06 Méthodes de traitement de troubles oculaires
BR112018070497-0A BR112018070497B1 (pt) 2016-04-07 2017-04-06 Métodos e formulações farmacêuticas para tratamento de condições oculares
EA201892265A EA201892265A1 (ru) 2016-04-07 2017-04-06 Способы лечения офтальмологических заболеваний
US16/091,830 US10709707B2 (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions
CN202210034408.5A CN114533737B (zh) 2016-04-07 2017-04-06 治疗眼部病状的方法
KR1020237000103A KR102512777B1 (ko) 2016-04-07 2017-04-06 안구 장애의 치료 방법
SG11201808650QA SG11201808650QA (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions
EP17718304.3A EP3439661B1 (fr) 2016-04-07 2017-04-06 Méthodes de traitement de troubles oculaires
IL262102A IL262102B (en) 2016-04-07 2018-10-03 Methods for treating eye conditions
PH12018502154A PH12018502154A1 (en) 2016-04-07 2018-10-05 Methods of treating ocular conditions
ZA2018/07438A ZA201807438B (en) 2016-04-07 2018-11-06 Methods of treating ocular conditions
US16/852,225 US20200345734A1 (en) 2016-04-07 2020-04-17 Methods of treating ocular conditions
IL290069A IL290069B2 (en) 2016-04-07 2022-01-24 Methods for treating eye conditions
JP2022095460A JP2022120125A (ja) 2016-04-07 2022-06-14 眼状態の治療方法
JP2024086805A JP2024103594A (ja) 2016-04-07 2024-05-29 眼状態の治療方法
US18/825,758 US20250000861A1 (en) 2016-04-07 2024-09-05 Methods of treating ocular conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319648P 2016-04-07 2016-04-07
US62/319,648 2016-04-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/091,830 A-371-Of-International US10709707B2 (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions
US16/852,225 Continuation US20200345734A1 (en) 2016-04-07 2020-04-17 Methods of treating ocular conditions

Publications (2)

Publication Number Publication Date
WO2017177024A1 WO2017177024A1 (fr) 2017-10-12
WO2017177024A8 true WO2017177024A8 (fr) 2018-11-08

Family

ID=58549326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/026385 WO2017177024A1 (fr) 2016-04-07 2017-04-06 Méthodes de traitement de troubles oculaires

Country Status (20)

Country Link
US (3) US10709707B2 (fr)
EP (2) EP3970724A1 (fr)
JP (3) JP7090551B2 (fr)
KR (2) KR102512777B1 (fr)
CN (3) CN109310692B (fr)
AU (1) AU2017248276B2 (fr)
CA (1) CA3020170A1 (fr)
DK (1) DK3439661T3 (fr)
EA (1) EA201892265A1 (fr)
ES (1) ES2893126T3 (fr)
IL (3) IL299204A (fr)
MX (2) MX385698B (fr)
MY (1) MY199237A (fr)
NZ (1) NZ746468A (fr)
PH (1) PH12018502154A1 (fr)
PT (1) PT3439661T (fr)
SG (1) SG11201808650QA (fr)
TW (1) TWI790997B (fr)
WO (1) WO2017177024A1 (fr)
ZA (1) ZA201807438B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
CN107106542B (zh) 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
EP3970724A1 (fr) * 2016-04-07 2022-03-23 Oyster Point Pharma, Inc. Méthodes de traitement de troubles oculaires
WO2020014217A1 (fr) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Méthodes de traitement d'états oculaires
TW202019417A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之正向異位調節劑與菸鹼乙醯膽鹼受體促效劑之組合
EP4142734A1 (fr) 2020-04-28 2023-03-08 Oyster Point Pharma, Inc. Administration locale d'agonistes du récepteur nicotinique de l'acétylcholine pour l'inhibition d'infections à coronavirus
BR112023023250A2 (pt) * 2021-05-07 2024-01-23 Oyster Point Pharma Inc Co-terapia com vetor e agonista nicotínico

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
CA2468705A1 (fr) 2001-11-29 2003-06-05 Pfizer Products Inc. Sels succiniques de 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene et compositions pharmaceutiques associees
WO2004039366A1 (fr) * 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Agonistes nicotiniques de l'acetylcholine dans le traitement du glaucome et d'une neuropathie de la retine
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
BRPI0515932A (pt) 2004-10-15 2008-08-12 Pfizer Prod Inc composições e métodos para distribuição intranasal, bucal, sublingual e pulmonar de vareniclina
WO2006100075A2 (fr) 2005-03-22 2006-09-28 Niconovum Ab Utilisation d'un edulcorant artificiel pour renforcer l'absorption de la nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
RS51970B (en) 2007-02-02 2012-02-29 Pfizer Products Inc. TRICYCLIC UNITS AND THEIR USE AS MODULATORS OF GLUCOCORTICOID RECEPTORS
WO2008157365A2 (fr) * 2007-06-15 2008-12-24 Targacept, Inc. Procédés ou utilisations et compositions pour traiter ou empêcher la douleur neuropathique
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
WO2009111550A1 (fr) 2008-03-05 2009-09-11 Targacept, Inc. Amides de diazabicycloalcanes sélectives d'un sous-type de récepteur d'acétylcholine nicotinique
EP2344496A1 (fr) 2008-09-05 2011-07-20 Targacept Inc. Amides de diazabicyclooctanes et leurs utilisations
WO2010028011A1 (fr) 2008-09-05 2010-03-11 Targacept, Inc. Amides de diazabicyclononanes et leurs utilisations
MX2011003306A (es) * 2008-10-14 2011-09-01 Psychogenics Inc Ligandos nicotinicos de receptor de acetilcolina y los usos de los mismos.
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
CA2742366C (fr) * 2008-12-01 2020-09-22 Targacept, Inc. Synthese et les formes salines de (r)((e)(pyrrolidin-3-ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
CA2763551A1 (fr) * 2009-06-17 2010-12-23 Targacept, Inc. Inversion d'une dyskinesie induite par le l-dopa par des ligands de recepteur nicotinique neuronal
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
BR112014007485B1 (pt) 2011-10-20 2022-05-31 Novartis Ag Métodos para prever responsividade terapêutica de um indivíduo a tratamento com um ativador do receptor de acetilcolina nicotínico alfa 7, e usos do referido ativador
US20140357971A1 (en) 2011-11-30 2014-12-04 Diagnostear Ltd. Dry eye diagnostic
CN107106542B (zh) * 2014-10-20 2020-05-08 奥伊斯特普安生物制药公司 治疗眼部病状的方法
EP3970724A1 (fr) * 2016-04-07 2022-03-23 Oyster Point Pharma, Inc. Méthodes de traitement de troubles oculaires

Also Published As

Publication number Publication date
KR102512777B1 (ko) 2023-03-23
TW201737917A (zh) 2017-11-01
ZA201807438B (en) 2024-09-25
JP7090551B2 (ja) 2022-06-24
KR102485299B1 (ko) 2023-01-06
KR20190005859A (ko) 2019-01-16
AU2017248276A1 (en) 2018-11-22
US20200345734A1 (en) 2020-11-05
ES2893126T8 (es) 2022-05-23
MY199237A (en) 2023-10-22
MX385698B (es) 2025-03-18
IL262102A (en) 2018-11-29
EP3970724A1 (fr) 2022-03-23
CN114533737B (zh) 2024-05-31
MX2018012230A (es) 2019-03-28
CN114432313A (zh) 2022-05-06
SG11201808650QA (en) 2018-10-30
CN109310692A (zh) 2019-02-05
PT3439661T (pt) 2021-09-30
CA3020170A1 (fr) 2017-10-12
EP3439661B1 (fr) 2021-08-04
JP2024103594A (ja) 2024-08-01
MX2021010399A (es) 2022-01-18
IL299204A (en) 2023-02-01
CN114533737A (zh) 2022-05-27
AU2017248276B2 (en) 2023-07-13
IL290069A (en) 2022-03-01
CN109310692B (zh) 2022-01-25
NZ785093A (en) 2024-07-05
EA201892265A1 (ru) 2019-04-30
ES2893126T3 (es) 2022-02-08
DK3439661T3 (da) 2021-10-18
US20190201397A1 (en) 2019-07-04
TWI790997B (zh) 2023-02-01
IL290069B2 (en) 2023-05-01
IL290069B1 (en) 2023-01-01
NZ746468A (en) 2023-06-30
EP3439661A1 (fr) 2019-02-13
BR112018070497A2 (pt) 2019-01-29
JP2019513759A (ja) 2019-05-30
US20250000861A1 (en) 2025-01-02
IL262102B (en) 2022-03-01
WO2017177024A1 (fr) 2017-10-12
PH12018502154A1 (en) 2019-07-08
US10709707B2 (en) 2020-07-14
JP2022120125A (ja) 2022-08-17
KR20230010813A (ko) 2023-01-19
TW202320785A (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
WO2017177024A8 (fr) Méthodes de traitement de troubles oculaires
MA49279A (fr) Compositions d&#39;anticorps optimisées pour le traitement de troubles oculaires
MA53937A (fr) Compositions comprenant des souches bactériennes
MA44861B1 (fr) Modulateurs de la voie de réponse intégrée au stress
MA50786A (fr) Produit d&#39;association pour le traitement de troubles neurologiques et/ou psychiatriques
MA41013B1 (fr) Compositions comprenant des souches bactériennes
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
MA40240A (fr) Composés hétéroaryle d&#39;inhibition de la kinase
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
EP3777830C0 (fr) Composition ophtalmique pour le traitement de la maladie de l&#39; oeil sec
MA50441A (fr) Nouvelle association d&#39;agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild)
EP3180022A4 (fr) Cassette d&#39;expression améliorée pour le conditionnement et l&#39;expression de variantes du facteur viii pour le traitement des troubles de l&#39;hémostase
MA50406B1 (fr) Inhibiteurs pyrazole de magl
EP3402533A4 (fr) Méthodes et compositions pour le traitement d&#39;une maladie neurologique
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
MA44426B1 (fr) Compositions et méthodes pour diminier l&#39;expression de tau
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EP3445352A4 (fr) Compositions pour le traitement de troubles liés à l&#39;hyperkératose
MA51056A (fr) Compositions et méthodes pour le traitement d&#39;affections métaboliques
EP3405191A4 (fr) Méthodes et compositions pour le traitement de l&#39;hyperhidrose
EP3445451A4 (fr) Compositions et méthodes pour le traitement de troubles lysosomaux et de troubles caractérisés par un dysfonctionnement lysosomal
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA54792A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
EA201790893A1 (ru) Способы лечения офтальмологических расстройств

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11201808650Q

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 3020170

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018553080

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018070497

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20187032218

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017718304

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017248276

Country of ref document: AU

Date of ref document: 20170406

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017718304

Country of ref document: EP

Effective date: 20181107

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17718304

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 112018070497

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181004